Missing Links? Citation Matrix | Graphs | Glossary HistCite Guide About |
Nodes: 1975,
Authors: 5409,
Journals: 512,
Outer References: 13295,
Words: 3300
Collection span: 1980 - 2004
View: Overview. Sorted by LCR.
Page 1: 1 2 3 4 5 6 7
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
---|---|---|---|---|---|
1 | 156 | 221 | 1706 2003 CLINICAL THERAPEUTICS 25(2):342-395 Matthews SJ; McCoy C Thalidomide: A review of approved and investigational uses | 2 | 6 |
2 | 151 | 187 | 1581 2003 ANNALS OF PHARMACOTHERAPY 37(9):1307-1320 Nasca MR; Micali G; Cheigh NH; West LE; West DP Dermatologic and nondermatologic uses of thalidomide | 1 | 1 |
3 | 128 | 159 | 1943 2004 LANCET 363(9423):1802-1811 Franks ME; Macpherson GR; Figg WD Thalidomide | 0 | 0 |
4 | 102 | 164 | 1440 2002 DRUGS & AGING 19(2):85-100 Zhou SF; Kestell P; Tingle MD; Paxton JW Thalidomide in cancer treatment - A potential role in the elderly? | 4 | 5 |
5 | 99 | 191 | 1087 2001 BIODRUGS 15(10):681-703 Meierhofer C; Dunzendorfer S; Wiedermann CJ Theoretical basis for the activity of thalidomide | 7 | 14 |
6 | 92 | 148 | 1028 2000 NATIONAL MEDICAL JOURNAL OF INDIA 13(3):132-141 Grover JK; Vats V; Gopalakrishna R; Ramam M Thalidomide: A re-look | 2 | 3 |
7 | 92 | 115 | 1177 2001 DERMATOLOGIC CLINICS 19(1):87-+ Radomsky CL; Levine N Thalidomide | 4 | 8 |
8 | 85 | 116 | 881 2000 ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE 127(6-7):603-613 Laffitte E; Revuz J Thalidomide | 7 | 9 |
9 | 80 | 118 | 1415 2002 CANCER INVESTIGATION 20(5-6):835-848 Baidas S; Tfayli A; Bhargava P Thalidomide: An old drug with new clinical applications | 1 | 3 |
10 | 75 | 113 | 894 2000 BIODRUGS 13(4):255-265 Kontogiannis V; Powell RJ Use of thalidomide in dermatological indications | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
11 | 75 | 130 | 1423 2002 CLINICAL AND EXPERIMENTAL RHEUMATOLOGY 20(5):709-718 Ossandon A; Cassara EAM; Priori R; Valesini G Thalidomide: focus on its employment in rheumatologic diseases | 2 | 4 |
12 | 74 | 101 | 546 1996 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 35(6):969-979 Tseng S; Pak G; Washenik K; Pomeranz MK; Shupack JL Rediscovering thalidomide: A review of its mechanism of action, side effects, and potential uses | 78 | 117 |
13 | 73 | 144 | 1720 2003 EXPERT OPINION ON INVESTIGATIONAL DRUGS 12(7):1211-1225 Fanelli M; Sarmiento R; Gattuso D; Carillio G; Capaccetti B; Vacca A; Roccaro AM; Gasparini G Thalidomide: a new anticancer drug? | 3 | 7 |
14 | 70 | 82 | 1843 2004 ANNALS OF ONCOLOGY 15(8):1151-1160 Eleutherakis-Papaiakovou V; Bamias A; Dimopoulos MA Thalidomide in cancer medicine | 0 | 0 |
15 | 69 | 136 | 868 1999 TERATOLOGY 60(5):306-321 Miller MT; Stromland K Teratogen update: Thalidomide: A review, with a focus on ocular findings and new potential uses | 7 | 19 |
16 | 69 | 104 | 1826 2003 SWISS MEDICAL WEEKLY 133(5-6):77-87 von Moos R; Stolz R; Cerny T; Gillessen S Thalidomide: from tragedy to promise | 1 | 1 |
17 | 66 | 87 | 742 1998 SEMINARS IN CUTANEOUS MEDICINE AND SURGERY 17(4):231-242 Stirling DI Thalidomide and its impact in dermatology | 14 | 17 |
18 | 66 | 77 | 1814 2003 POSTGRADUATE MEDICAL JOURNAL 79(929):127-132 Gordon JN; Goggin PM Thalidomide and its derivatives: emerging from the wilderness | 0 | 3 |
19 | 64 | 215 | 541 1996 JOURNAL OF INFLAMMATION 46(4):177-211 Zwingenberger K; Wnendt S Immunomodulation by thalidomide: Systematic review of the literature and of unpublished observations | 33 | 38 |
20 | 63 | 112 | 1298 2002 ANNUAL REVIEW OF MEDICINE 53:629-657 Richardson P; Hideshima T; Anderson K Thalidomide: Emerging role in cancer medicine | 23 | 36 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
21 | 62 | 96 | 877 2000 AMERICAN JOURNAL OF MEDICINE 108(6):487-495 Calabrese L; Fleischer AB Thalidomide: Current and potential clinical applications | 60 | 103 |
22 | 59 | 87 | 1188 2001 EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY 57(5):365-376 Eriksson T; Bjorkman S; Hoglund P Clinical pharmacology of thalidomide | 22 | 32 |
23 | 58 | 116 | 1072 2001 ANNALS OF MEDICINE 33(8):516-525 Ginsburg PM; Dassopoulos T; Ehrenpreis ED Thalidomide treatment for refractory Crohn's disease: a review. of the history, pharmacological mechanisms and clinical literature | 9 | 13 |
24 | 58 | 107 | 1433 2002 CROATIAN MEDICAL JOURNAL 43(3):274-285 Mujagic H; Chabner BA; Mujagic Z Mechanisms of action and potential therapeutic uses of thalidomide | 1 | 2 |
25 | 57 | 82 | 1432 2002 CRITICAL REVIEWS IN IMMUNOLOGY 22(5-6):425-437 Dredge K; Marriott JB; Dalgleish AG Immunological effects of thalidomide and its chemical and functional analogs | 0 | 2 |
26 | 57 | 70 | 1739 2003 JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES 785(1):165-173 Zhou SF; Lia Y; Kestell P; Paxton JW Determination of thalidomide in transport buffer for Caco-2 cell monolayers by high-performance liquid chromatography with ultraviolet detection | 0 | 0 |
27 | 53 | 61 | 1307 2002 BIOMEDICINE & PHARMACOTHERAPY 56(1):4-12 Singhal S; Mehta J Thalidomide in cancer | 17 | 21 |
28 | 53 | 61 | 1541 2002 ORAL ONCOLOGY 38(6):527-531 Porter SR; Jorge J Thalidomide: a role in oral oncology? | 0 | 1 |
29 | 51 | 221 | 964 2000 CLINICS IN DERMATOLOGY 18(1):131-145 Sanchez MR Miscellaneous treatments: Thalidomide, potassium iodide, levamisole, clofazimine, colchicine, and D-penicillamine | 0 | 3 |
30 | 51 | 96 | 1049 2000 SEMINARS IN HEMATOLOGY 37(1):5-14 Stirling DI Pharmacology of thalidomide | 21 | 23 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
31 | 51 | 94 | 1747 2003 JOURNAL OF CLINICAL ONCOLOGY 21(23):4444-4454 Dimopoulos MA; Anagnostopoulos A; Weber D Treatment of plasma cell dyserasias with thalidomide and its derivatives | 1 | 2 |
32 | 50 | 73 | 1086 2001 BIODRUGS 15(3):163-172 Singhal S; Mehta J Thalidomide in cancer - Potential uses and limitations | 12 | 16 |
33 | 50 | 93 | 1311 2002 BIOMEDICINE & PHARMACOTHERAPY 56(3):115-128 Richardson P; Hideshima T; Anderson K Thalidomide in multiple myeloma | 5 | 6 |
34 | 50 | 83 | 1957 2004 MAYO CLINIC PROCEEDINGS 79(7):899-903 Rajkumar SV Thalidomide: Tragic past and promising future | 0 | 0 |
35 | 49 | 86 | 1707 2003 CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY 46:S49-S57 Macpherson GR; Franks M; Tomoaia-Cotisel A; Ando Y; Price DK; Figg WD Current status of thalidomide and its role in the treatment of metastatic prostate cancer | 1 | 2 |
36 | 48 | 74 | 607 1997 INTERNATIONAL JOURNAL OF DERMATOLOGY 36(12):881-887 Calderon P; Anzilotti M; Phelps R Thalidomide in dermatology. New indications for an old drug | 22 | 27 |
37 | 48 | 79 | 761 1999 BIODRUGS 11(6):409-416 Powell RJ Thalidomide - Current uses | 1 | 2 |
38 | 48 | 68 | 1208 2001 HAUTARZT 52(8):726-733 Kuhn A; Hefter H; Ruzicka T; Lehmann P Rediscovery of thalidomide. Successful treatment of discoid lupus erythematosus | 0 | 0 |
39 | 45 | 95 | 965 2000 CURRENT OPINION IN ONCOLOGY 12(6):564-573 Thomas DA; Kantarjian HM Current role of thalidomide in cancer treatment | 16 | 41 |
40 | 44 | 140 | 1183 2001 DRUG SAFETY 24(2):87-117 Clark TE; Edom N; Larson J; Lindsey LJ Thalomid (R) (Thalidomide) capsules - A review of the first 18 months of spontaneous postmarketing adverse event surveillance, including off-label prescribing | 11 | 14 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
41 | 44 | 67 | 1184 2001 DRUGS 61(6):777-787 Bousvaros A; Mueller B Thalidomide in gastrointestinal disorders | 4 | 8 |
42 | 44 | 67 | 1806 2003 ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY AND ENDODONTICS 95(5):576-585 Hegarty A; Hodgson T; Porter S Thalidomide for the treatment of recalcitrant oral Crohn's disease and orofacial granulomatosis | 1 | 2 |
43 | 43 | 65 | 1563 2003 AMERICAN JOURNAL OF CLINICAL DERMATOLOGY 4(6):379-387 Pelle MT; Werth VP Thalidomide in cutaneous lupus erythematosus | 0 | 0 |
44 | 42 | 65 | 1890 2004 CLINICAL PHARMACOKINETICS 43(5):311-327 Teo SK; Colburn WA; Tracewell WG; Kook KA; Stirling DI; Jaworsky MS; Scheffler MA; Thomas SD; Laskin OL Clinical pharmacokinetics of thalidomide | 1 | 1 |
45 | 41 | 106 | 267 1990 ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE 117(4):313-321 REVUZ J THALIDOMIDE | 16 | 21 |
46 | 41 | 120 | 971 2000 DRUGS 60(2):273-292 Peuckmann V; Fisch M; Bruera E Potential novel uses of thalidomide - Focus on palliative care | 27 | 40 |
47 | 41 | 78 | 1812 2003 PHARMACOTHERAPY 23(4):481-493 Okafor MC Thalidomide for erythema nodosum leprosum and other applications | 0 | 0 |
48 | 40 | 51 | 997 2000 JCR-JOURNAL OF CLINICAL RHEUMATOLOGY 6(1):19-26 Lenardo TM; Calabrese LH The role of thalidomide in the treatment of rheumatic disease | 4 | 4 |
49 | 40 | 53 | 1189 2001 EXPERT OPINION ON BIOLOGICAL THERAPY 1(4):675-682 Marriott JB; Muller G; Stirling D; Dalgleish AG Immunotherapeutic and antitumour potential of thalidomide analogues | 12 | 16 |
50 | 40 | 59 | 1709 2003 CURRENT OPINION IN DRUG DISCOVERY & DEVELOPMENT 6(1):92-99 Meierhofer C; Wiedermann CJ New insights into the pharmacological and toxicological effects of thalidomide | 3 | 3 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
51 | 40 | 78 | 1901 2004 EXPERT OPINION ON THERAPEUTIC PATENTS 14(2):215-229 Luzzio FA; Figg WD Thalidomide analogues: derivatives of an orphan drug with diverse biological activity | 0 | 0 |
52 | 39 | 67 | 1479 2002 JOURNAL OF CELLULAR AND MOLECULAR MEDICINE 6(2):160-174 Kumar S; Witzig TE; Rajkumar SV Thalidomide as an anti-cancer agent | 6 | 10 |
53 | 39 | 57 | 1965 2004 NATURE REVIEWS CANCER 4(4):314-322 Bartlett JB; Dredge K; Dalgleish AG Timeline - The evolution of thalidomide and its IMiD derivatives as anticancer agents | 2 | 2 |
54 | 38 | 52 | 813 1999 IMMUNOLOGY TODAY 20(12):538-540 Marriott JB; Muller G; Dalgleish AG Thalidomide as an emerging immunotherapeutic agent | 38 | 47 |
55 | 37 | 44 | 1218 2001 JOINT BONE SPINE 68(6):582-587 Combe B Thalidomide: new indications? | 1 | 3 |
56 | 37 | 67 | 1494 2002 JOURNAL OF IMMUNOLOGY 168(6):2644-2651 Majumdar S; Lamothe B; Aggarwal BB Thalidomide suppresses NF-kappa B activation induced by TNF and H2O2, but not that activated by ceramide, lipopolysaccharides, or phorbol ester | 12 | 25 |
57 | 36 | 60 | 1164 2001 CELLULAR AND MOLECULAR BIOLOGY 47(7):1105-1114 Settles B; Stevenson A; Wilson K; Mack C; Ezell T; Davis MF; Taylor LD Down-regulation of cell adhesion molecules LFA-1 and ICAM-1 after in vitro treatment with the anti-TNF-alpha agent thalidomide | 7 | 10 |
58 | 35 | 95 | 1817 2003 SCHMERZ 17(3):204-+ Peuckmann V; Strumpf M; Zenz M; Bruera E Novel potential uses of thalidomide in the management of pain? A review of the literature | 0 | 0 |
59 | 33 | 37 | 1421 2002 CLINICAL AND EXPERIMENTAL IMMUNOLOGY 130(1):75-84 Marriott JB; Clarke IA; Dredge K; Muller G; Stirling D; Dalgleish AG Thalidomide and its analogues have distinct and opposing effects on TNF-alpha and TNFR2 during co-stimulation of both CD4(+) and CD8(+) T cells | 17 | 19 |
60 | 33 | 53 | 1434 2002 CURRENT OPINION IN ONCOLOGY 14(6):635-640 Raje N; Anderson KC Thalidomide and immunomodulatory drugs as cancer therapy | 8 | 14 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
61 | 32 | 44 | 1068 2001 AMERICAN JOURNAL OF THE MEDICAL SCIENCES 321(5):321-326 Moraes M; Russo G Thalidomide and its dermatologic uses | 3 | 9 |
62 | 32 | 40 | 1867 2004 BRITISH JOURNAL OF CANCER 90(5):955-961 Bartlett JB; Michael A; Clarke IA; Dredge K; Nicholson S; Kristeleit H; Polychronis A; Pandha H; Muller GW; Stirling DI; Zeldis J; Dalgleish AG Phase 1 study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers | 1 | 1 |
63 | 31 | 89 | 351 1993 ARCHIVES OF TOXICOLOGY 67(1):1-17 NEUBERT R; NOGUEIRA AC; NEUBERT D THALIDOMIDE DERIVATIVES AND THE IMMUNE-SYSTEM .1. CHANGES IN THE PATTERN OF INTEGRIN RECEPTORS AND OTHER SURFACE-MARKERS ON LYMPHOCYTE-T SUBPOPULATIONS OF MARMOSET BLOOD | 40 | 49 |
64 | 31 | 67 | 1160 2001 CANCER 92(9):2364-2373 Tseng JE; Glisson BS; Khuri FR; Shin DM; Myers JN; El-Naggar AK; Roach JS; Ginsberg LE; Thall PF; Wang XM; Teddy S; Lawhorn KN; Zentgraf RE; Steinhaus GD; Pluda JM; Abbruzzese JL; Hong WK; Herbst RS Phase II study of the antiangiogenesis agent thalidomide in recurrent or metastatic squamous cell carcinoma of the head and neck | 7 | 14 |
65 | 30 | 53 | 753 1999 ARCHIVES OF DERMATOLOGY 135(9):1079-1087 Duong DJ; Spigel GT; Moxley RT; Gaspari AA American experience with low-dose thalidomide therapy for severe cutaneous lupus erythematosus | 20 | 29 |
66 | 30 | 49 | 1178 2001 DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT 126(42):1178-1182 Tuinmann G; Hegewisch-Becker S; Hossfeld DK New indications for thalidomide | 2 | 3 |
67 | 30 | 71 | 1305 2002 BIOLOGICAL & PHARMACEUTICAL BULLETIN 25(5):597-604 Marks MG; Shi JD; Fry MO; Xiao ZL; Trzyna M; Pokala V; Ihnat MA; Li PK Effects of putative hydroxylated thalidomide metabolites on blood vessel density in the chorioallantoic membrane (CAM) assay and on tumor and endothelial cell proliferation | 6 | 9 |
68 | 30 | 45 | 1312 2002 BIOMEDICINE & PHARMACOTHERAPY 56(4):194-199 Ng SSW; Brown M; Figg WD Thalidomide, an antiangiogenic agent with clinical activity in cancer | 5 | 6 |
69 | 30 | 59 | 1390 2002 BLOOD REVIEWS 16(4):207-215 Strasser K; Ludwig H Thalidomide treatment in multiple myeloma | 3 | 4 |
70 | 29 | 60 | 697 1998 EXPERIMENTAL HEMATOLOGY 26(3):217-221 Or R; Feferman R; Shoshan S Thalidomide reduces vascular density in granulation tissue of subcutaneously implanted polyvinyl alcohol sponges in guinea pigs | 18 | 24 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
71 | 29 | 79 | 751 1999 ANNALS OF THE RHEUMATIC DISEASES 58:107-113 Corral LG; Kaplan G Immunomodulation by thalidomide and thalidomide analogues | 13 | 18 |
72 | 29 | 42 | 1242 2001 LUPUS 10(3):188-192 Karim MY; Ruiz-Irastorza G; Khamashta MA; Hughes GRV Update on therapy - thalidomide in the treatment of lupus | 6 | 13 |
73 | 29 | 56 | 1973 2004 TOXICOLOGICAL SCIENCES 81(2):379-389 Teo SK; Denny KH; Stirling DI; Thomas SD; Morseth S; Hoberman AM Effects of thalidomide on developmental, peri-and postnatal function in female New Zealand white rabbits and offspring | 0 | 0 |
74 | 28 | 38 | 354 1993 BONE MARROW TRANSPLANTATION 12:S26-S28 EHNINGER G; EGER K; STUHLER A; SCHULER U THALIDOMIDE - THE NEED FOR A NEW CLINICAL-EVALUATION OF AN OLD DRUG | 7 | 8 |
75 | 28 | 50 | 589 1997 CLINICAL AND EXPERIMENTAL IMMUNOLOGY 110(2):151-154 McHugh SM; Rowland TL Thalidomide and derivatives: immunological investigations of tumour necrosis factor-alpha (TNF-alpha) inhibition suggest drugs capable of selective gene regulation | 17 | 32 |
76 | 28 | 70 | 1254 2001 ONCOLOGY-NEW YORK 15(7):867-874 Rajkumar SV Current status of thalidomide in the treatment of cancer | 9 | 14 |
77 | 27 | 36 | 1014 2000 JOURNAL OF PHARMACY AND PHARMACOLOGY 52(7):807-817 Eriksson T; Bjorkman S; Roth B; Hoglund P Intravenous formulations of the enantiomers of thalidomide: Pharmacokinetic and initial pharmacodynamic characterization in man | 10 | 17 |
78 | 27 | 53 | 1219 2001 JOURNAL OF BIOLOGICAL CHEMISTRY 276(25):22382-22387 Keifer JA; Guttridge DC; Ashburner BP; Baldwin AS Inhibition of NF-kappa B activity by thalidomide through suppression of I kappa B kinase activity | 33 | 57 |
79 | 27 | 34 | 1297 2002 ANNALS OF PHARMACOTHERAPY 36(3):521-525 Bessmertny O; Pham T Thalidomide use in pediatric patients | 1 | 2 |
80 | 27 | 44 | 1472 2002 INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY 83(2):99-104 Arrieta O; Guevara P; Tamariz J; Rembao D; Rivera E; Sotelo J Antiproliferative effect of thalidomide alone and combined with carmustine against C6 rat glioma | 1 | 3 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
81 | 27 | 37 | 1576 2003 ANNALS OF HEMATOLOGY 82(9):558-564 Huang SY; Tang JL; Yao M; Ko BS; Hong RL; Tsai W; Wang CH; Tien HF; Shen MC; Chen YC Reduction of leukocyte count is associated with thalidomide response in treatment of multiple myeloma | 0 | 0 |
82 | 27 | 54 | 1946 2004 LEUKEMIA 18(4):856-863 Garcia-Sanz R; Gonzalez-Porras JR; Hernandez JM; Polo-Zarzuela M; Sureda A; Barrenetxea C; Palomera L; Lopez R; Grande-Garcia C; Alegre A; Vargas-Pabon M; Gutierrez ON; Rodriguez JA; San Miguel JF The oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is effective in relapsed/refractory multiple myeloma | 0 | 1 |
83 | 26 | 174 | 893 2000 BIOCHEMICAL PHARMACOLOGY 59(12):1489-1499 Stephens TD; Bunde CJW; Fillmore BJ Mechanism of action in thalidomide teratogenesis | 24 | 36 |
84 | 26 | 123 | 1176 2001 CURRENT OPINION IN ONCOLOGY 13(5):374-381 Krown SE Management of Kaposi sarcoma: the role of interferon and thalidomide | 2 | 17 |
85 | 26 | 91 | 1313 2002 BIOORGANIC & MEDICINAL CHEMISTRY 10(3):461-479 Hashimoto Y Structural development of biological response modifiers based on thalidomide | 8 | 15 |
86 | 26 | 38 | 1698 2003 CLINICAL CANCER RESEARCH 9(5):1680-1688 Lu J; Palmer BD; Kestell P; Browett P; Baguley BC; Muller G; Ching LM Thalidomide metabolites in mice and patients with multiple myeloma | 7 | 8 |
87 | 26 | 38 | 1790 2003 LEUKEMIA & LYMPHOMA 44(7):1141-1146 Flowers MED; Martin PJ Evaluation of thalidomide for treatment or prevention of chronic graft-versus-host disease | 0 | 0 |
88 | 25 | 61 | 378 1994 ADVERSE DRUG REACTIONS AND TOXICOLOGICAL REVIEWS 13(2):65-76 DARCY PF; GRIFFIN JP THALIDOMIDE REVISITED | 22 | 27 |
89 | 25 | 52 | 830 1999 JOURNAL OF INVESTIGATIVE DERMATOLOGY 113(5):720-724 Nasca MR; O'Toole EA; Palicharla P; West DP; Woodley DT Thalidomide increases human keratinocyte migration and proliferation | 6 | 15 |
90 | 25 | 54 | 1425 2002 CLINICAL CANCER RESEARCH 8(6):1964-1973 Ando Y; Fuse E; Figg WD Thalidomide metabolism by the CYP2C subfamily | 14 | 15 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
91 | 25 | 47 | 1847 2004 ARCHIVES OF DERMATOLOGY 140(7):845-849 Maurer T; Poncelet A; Berger T Thalidomide treatment for prurigo nodularis in human immunodeficiency virus-infected subjects - Efficacy and risk of neuropathy | 0 | 0 |
92 | 25 | 45 | 1935 2004 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 50(2):235-241 Nguyen YT; Dupuy A; Cordoliani F; Vignon-Pennamen MD; Lebbe C; Morel P; Rybojad M Treatment of cutaneous sarcoidosis with thalidomide | 0 | 0 |
93 | 24 | 32 | 1149 2001 BRITISH JOURNAL OF DERMATOLOGY 144(2):310-315 Chave TA; Finlay AY; Knight AG; All-Wales Dermatology Audit Comm Thalidomide usage in Wales: the need to follow guidelines | 1 | 1 |
94 | 24 | 28 | 1234 2001 JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION 32(3):322-324 Strauss RS; Das FM Thalidomide-induced sensory neuropathy | 2 | 3 |
95 | 24 | 39 | 1389 2002 BLOOD 100(12):4162-4168 Yaccoby S; Johnson CL; Mahaffey SC; Wezeman MJ; Barlogie B; Epstein J Antimyeloma efficacy of thalidomide in the SCID-hu model | 1 | 6 |
96 | 24 | 47 | 1857 2004 BIRTH DEFECTS RESEARCH PART B-DEVELOPMENTAL AND REPRODUCTIVE TOXICOLOGY 71(1):1-16 Teo SK; Denny KH; Stirling DI; Thomas SD; Morseth SL; Hoberman AM Effects of thalidomide on reproductive function and early embryonic development in male and female New Zealand white rabbits | 1 | 1 |
97 | 24 | 52 | 1895 2004 DRUGS OF TODAY 40(3):197-204 Joglekar S; Levin M The promise of thalidomide: Evolving indications | 0 | 0 |
98 | 24 | 42 | 1925 2004 JOURNAL OF IMMUNOLOGY 172(8):5103-5109 Gockel HR; Lugering A; Heidemann J; Schmidt M; Domschke W; Kucharzik T; Lugering N Thalidomide induces apoptosis in human monocytes by using a cytochrome c-dependent pathway | 0 | 0 |
99 | 23 | 42 | 388 1994 BONE MARROW TRANSPLANTATION 14(6):937-942 COLE CH; ROGERS PCJ; PRITCHARD S; PHILLIPS G; CHAN KW THALIDOMIDE IN THE MANAGEMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE IN CHILDREN FOLLOWING BONE-MARROW TRANSPLANTATION | 25 | 30 |
100 | 23 | 38 | 450 1995 CLINICAL INFECTIOUS DISEASES 20(2):250-254 PATERSON DL; GEORGHIOU PR; ALLWORTH AM; KEMP RJ THALIDOMIDE AS TREATMENT OF REFRACTORY APHTHOUS ULCERATION RELATED TO HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION | 38 | 60 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
101 | 23 | 79 | 845 1999 MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS 425(1):153-167 Zhu XY; Zhang YP; Klopman G; Rosenkranz HS Thalidomide and metabolites: indications of the absence of 'genotoxic' carcinogenic potentials | 3 | 3 |
102 | 23 | 45 | 952 2000 CANCER CHEMOTHERAPY AND PHARMACOLOGY 46(2):135-141 Kestell P; Zhao LL; Baguley BC; Palmer BD; Muller G; Paxton JW; Ching LM Modulation of the pharmacokinetics of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice by thalidomide | 6 | 21 |
103 | 23 | 55 | 1257 2001 OPHTHALMIC RESEARCH 33(5):256-263 Baatz H; Tonessen B; Prada J; Pleyer U Thalidomide inhibits leukocyte-endothelium interaction in endotoxin-induced uveitis | 1 | 4 |
104 | 23 | 52 | 1278 2001 TOXICOLOGICAL SCIENCES 59(1):160-168 Teo SK; Evans MG; Brockman MJ; Ehrhart J; Morgan JM; Stirling DI; Thomas SD Safety profile of thalidomide after 53 weeks of oral administration in beagle dogs | 5 | 5 |
105 | 23 | 42 | 1495 2002 JOURNAL OF IMMUNOLOGY 168(10):4914-4919 Dredge K; Marriott JB; Todryk SM; Muller GW; Chen R; Stirling DI; Dalgleish AG Protective antitumor immunity induced by a costimulatory thalidomide analog in conjunction with whole tumor cell vaccination is mediated by increased Th1-type immunity | 14 | 29 |
106 | 23 | 30 | 1500 2002 JOURNAL OF LEUKOCYTE BIOLOGY 72(5):939-945 Mohty M; Stoppa AM; Blaise D; Isnardon D; Gastaut JA; Olive D; Gaugler A Differential regulation of dendritic cell function by the immunomodulatory drug thalidomide | 2 | 6 |
107 | 23 | 39 | 1796 2003 MAYO CLINIC PROCEEDINGS 78(1):34-39 Kumar S; Gertz MA; Dispenzieri A; Lacy MQ; Geyer SM; Iturria NL; Fonseca R; Hayman SR; Lust JA; Kyle RA; Greipp PR; Witzig TE; Rajkumar SV Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma | 9 | 21 |
108 | 22 | 61 | 117 1984 INTERNATIONAL JOURNAL OF DERMATOLOGY 23(9):598-602 GROSSHANS E; ILLY G THALIDOMIDE THERAPY FOR INFLAMMATORY DERMATOSES | 55 | 62 |
109 | 22 | 33 | 549 1996 LUPUS 5(4):257-258 Stevens RJ The place of thalidomide in the treatment of inflammatory disease | 3 | 5 |
110 | 22 | 80 | 694 1998 CURRENT MEDICINAL CHEMISTRY 5(3):163-178 Hashimoto Y Novel biological response modifiers derived from thalidomide | 16 | 38 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
111 | 22 | 30 | 745 1999 AIDS RESEARCH AND HUMAN RETROVIRUSES 15(12):1047-1052 Noormohamed FH; Youle MS; Higgs CJ; Kook KA; Hawkins DA; Lant AF; Thomas SD Pharmacokinetics and hemodynamic effects of single oral doses of thalidomide in asymptomatic human immunodeficiency virus-infected subjects | 13 | 13 |
112 | 22 | 35 | 787 1999 CANCER CHEMOTHERAPY AND PHARMACOLOGY 43:S78-S84 Dixon SC; Kruger EA; Bauer KS; Figg WD Thalidomide up-regulates prostate-specific antigen secretion from LNCaP cells | 8 | 14 |
113 | 22 | 32 | 809 1999 GASTROENTEROLOGY 117(6):1485-1488 Sands BE; Podolsky DK New life in a sleeper: Thalidomide and Crohn's disease | 8 | 25 |
114 | 22 | 34 | 1554 2002 THERAPEUTIC DRUG MONITORING 24(1):104-110 Price DK; Ando Y; Kruger EA; Weiss M; Figg WD 5 '-OH-thalidomide, a metabolite of thalidomide, inhibits angiogenesis | 9 | 10 |
115 | 22 | 30 | 1582 2003 ANTI-CANCER DRUGS 14(5):331-335 Dredge K; Dalgleish AG; Marriott JB Thalidomide analogs as emerging anti-cancer drugs | 3 | 8 |
116 | 22 | 28 | 1692 2003 CANCER RESEARCH 63(3):593-599 Marriott JB; Clarke IA; Czajka A; Dredge K; Childs K; Man HW; Schafer P; Govinda S; Muller GW; Stirling DI; Dalgleish AG A novel subclass of thalidomide analogue with anti-solid tumor activity in which caspase-dependent apoptosis is associated with altered expression of bcl-2 family proteins | 7 | 14 |
117 | 22 | 33 | 1888 2004 CLINICAL CANCER RESEARCH 10(17):5949-5956 Chung F; Lu J; Palmer BD; Kestell P; Browett P; Baguley BC; Tingle M; Ching LM Thalidomide pharmacokinetics and metabolite formation in mice, rabbits, and multiple myeloma patients | 0 | 0 |
118 | 21 | 64 | 263 1989 MEDICAL HYPOTHESES 30(2):105-109 GUNZLER V THALIDOMIDE - A THERAPY FOR THE IMMUNOLOGICAL CONSEQUENCES OF HIV INFECTION | 4 | 6 |
119 | 21 | 108 | 634 1997 MEDICAL HYPOTHESES 49(2):123-131 McCarty MF Thalidomide may impede cell migration in primates by down-regulating integrin beta-chains: Potential therapeutic utility in solid malignancies, proliferative retinopathy, inflammatory disorders, neointimal hyperplasia, and osteoporosis | 17 | 31 |
120 | 21 | 44 | 644 1997 NEW ENGLAND JOURNAL OF MEDICINE 336(21):1487-1493 Jacobson JM; Greenspan JS; Spritzler J; Ketter N; Fahey JL; Jackson JB; Fox L; Chernoff M; Wu AW; MacPhail LA; Vasquez GJ; Wohl DA Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection | 119 | 192 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
121 | 21 | 40 | 1005 2000 JOURNAL OF CLINICAL ONCOLOGY 18(14):2710-2717 Baidas SM; Winer EP; Fleming GF; Harris L; Pluda JM; Crawford JG; Yamauchi H; Isaacs C; Hanfelt J; Tefft M; Flockhart D; Johnson MD; Hawkins MJ; Lippman ME; Hayes DF Phase II evaluation of thalidomide in patients with metastatic breast cancer | 39 | 54 |
122 | 21 | 30 | 1073 2001 ANNALS OF ONCOLOGY 12(7):885-886 Thomas DA; Kantarjian HM The revitalization of thalidomide | 4 | 5 |
123 | 21 | 36 | 1283 2002 ALIMENTARY PHARMACOLOGY & THERAPEUTICS 16(6):1117-1124 Sabate JM; Villarejo J; Lemann M; Bonnet J; Allez M; Modigliani R An open-label study of thalidomide for maintenance therapy in responders to infliximab in chronically active and fistulizing refractory Crohn's disease | 4 | 15 |
124 | 21 | 37 | 1490 2002 JOURNAL OF CLINICAL ONCOLOGY 20(21):4319-4323 Rajkumar SV; Hayman S; Gertz MA; Dispenzieri A; Lacy MQ; Greipp PR; Geyer S; Iturria N; Fonseca R; Lust JA; Kyle RA; Witzig TE Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma | 33 | 57 |
125 | 21 | 42 | 1956 2004 MAYO CLINIC PROCEEDINGS 79(7):883-889 Mesa RA; Elliott MA; Schroeder G; Tefferi A Durable responses to thalidomide-based drug therapy for myelofibrosis with myeloid metaplasia | 1 | 1 |
126 | 21 | 45 | 1964 2004 MOLECULES AND CELLS 17(2):210-216 Kim YS; Kim JS; Jung HC; Song IS The effects of thalidomide on the stimulation of NF-kappa B activity and TNF-alpha production by lipopolysaccharide in a human colonic epithelial cell line | 0 | 0 |
127 | 20 | 85 | 379 1994 ADVERSE DRUG REACTIONS AND TOXICOLOGICAL REVIEWS 13(4):177-192 CRAWFORD CL USE OF THALIDOMIDE IN LEPROSY | 8 | 11 |
128 | 20 | 52 | 456 1995 EXPERIMENTAL HEMATOLOGY 23(9):978-985 FERNANDEZ LP; SCHLEGEL PG; BAKER J; CHEN YF; CHAO NJ DOES THALIDOMIDE AFFECT IL-2 RESPONSE AND PRODUCTION | 21 | 21 |
129 | 20 | 42 | 786 1999 BRITISH JOURNAL OF CANCER 80(5-6):716-723 Cao Z; Joseph WR; Browne WL; Mountjoy KG; Palmer BD; Baguley BC; Ching LM Thalidomide increases both intra-tumoural tumour necrosis factor-alpha production and anti-tumour activity in response to 5,6-dimethylxanthenone-4-acetic acid | 11 | 26 |
130 | 20 | 33 | 807 1999 GASTROENTEROLOGY 117(6):1271-1277 Ehrenpreis ED; Kane SV; Cohen LB; Cohen RD; Hanauer SB Thalidomide therapy for patients with refractory Crohn's disease: An open-label trial | 44 | 132 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
131 | 20 | 98 | 954 2000 CANCER TREATMENT REVIEWS 26(5):351-362 Rajkumar SV; Witzig TE A review of angiogenesis and antiangiogenic therapy with thalidomide in multiple myeloma | 29 | 53 |
132 | 20 | 32 | 1224 2001 JOURNAL OF CLINICAL PHARMACOLOGY 41(6):662-667 Teo SK; Scheffler MR; Kook KA; Tracewell WG; Colburn WA; Stirling DI; Thomas SD Thalidomide dose proportionality assessment following single doses to healthy subjects | 3 | 4 |
133 | 20 | 48 | 1263 2001 QUIMICA NOVA 24(5):683-688 Lima LM; Fraga CAM; Barreiro EJ The rebirth of a drug: Thalidomide | 0 | 1 |
134 | 20 | 24 | 1487 2002 JOURNAL OF CLINICAL ONCOLOGY 20(11):2607-2609 Eisen T Thalidomide in solid malignancies | 6 | 12 |
135 | 20 | 32 | 1555 2002 THERAPIE 57(6):524-529 Boulin M; Blanchet F; Isambert N; Solary E; Solier S; Collin B; Pernot C; Durnet-Archeray MJ Role of thalidomide with or without dexamethasone for refractory multiple myeloma | 0 | 0 |
136 | 19 | 39 | 270 1990 BIOMEDICINE & PHARMACOTHERAPY 44(4):199-204 HENEY D; BAILEY CC; LEWIS IJ THALIDOMIDE IN THE TREATMENT OF GRAFT-VERSUS-HOST DISEASE | 12 | 14 |
137 | 19 | 42 | 593 1997 CLINICAL NEUROPHARMACOLOGY 20(2):152-164 Zhu J; Bai XF; Mix E; vanderMeide PH; Zwingenberger K; Link H Thalidomide suppresses T-and B-cell responses to myelin antigen in experimental allergic neuritis | 3 | 4 |
138 | 19 | 33 | 703 1998 IMMUNOPHARMACOLOGY 40(1):11-20 Rowland TL; McHugh SM; Deighton J; Dearman RJ; Ewan PW; Kimber I Differential regulation by thalidomide and dexamethasone of cytokine expression in human peripheral blood mononuclear cells | 36 | 48 |
139 | 19 | 37 | 708 1998 JOURNAL OF EXPERIMENTAL MEDICINE 187(11):1885-1892 Haslett PAJ; Corral LG; Albert M; Kaplan G Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset | 144 | 179 |
140 | 19 | 36 | 802 1999 ETHIOPIAN MEDICAL JOURNAL 37(4):275-280 Shannon EJ 24th Kellersberger Memorial Lecture, 1999 thalidomide: Will the past overshadow a promising future? | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
141 | 19 | 38 | 886 2000 ANTI-CANCER DRUGS 11(10):787-791 Adlard JW Thalidomide in the treatment of cancer | 5 | 11 |
142 | 19 | 40 | 987 2000 HUMAN & EXPERIMENTAL TOXICOLOGY 19(11):615-622 Teo S; Evans M; Ehrhart J; Brockman M; Allen D; Morgan M; Stirling D; Thomas S Lack of peripheral neuropathy in Beagle dogs after 53 weeks oral administration of thalidomide capsules | 0 | 0 |
143 | 19 | 47 | 1274 2001 SEMINARS IN ONCOLOGY 28(6):597-601 D'Amato RJ; Lentzsch S; Anderson KC; Rogers MS Mechanism of action of thalidomide and 3-aminothalidomide in multiple myeloma | 0 | 10 |
144 | 19 | 51 | 1416 2002 CANCER INVESTIGATION 20(7-8):1051-1058 Jaslow R; Kaplan G; Lyons L; Michaeli J; Coleman M Thalidomide in multiple myeloma-from the clinic to the laboratory | 0 | 0 |
145 | 19 | 36 | 1445 2002 EUROPEAN JOURNAL OF PHARMACOLOGY 453(2-3):325-334 Thiele A; Bang R; Gutschow M; Rossol M; Loos S; Eger K; Tiegs G; Hauschildt S Cytokine modulation and suppression of liver injury by a novel analogue of thalidomide | 1 | 3 |
146 | 19 | 30 | 1474 2002 INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE 6(7):569-572 Fu LM; Fu-Liu CS Thalidomide and tuberculosis | 2 | 3 |
147 | 19 | 50 | 1676 2003 BRITISH JOURNAL OF HAEMATOLOGY 120(1):18-26 Cavenagh JD; Oakervee H; UK Myeloma Forum; BSCH Haematology Oncology Task For Thalidomide in multiple myeloma: Current status and future prospects | 15 | 18 |
148 | 19 | 40 | 1682 2003 BRITISH JOURNAL OF HAEMATOLOGY 122(4):607-616 Kropff MH; Lang N; Bisping G; Domine N; Innig G; Hentrich M; Mitterer M; Sudhoff T; Fenk R; Straka C; Heinecke A; Koch OM; Ostermann H; Berdel WE; Kienast J Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma | 5 | 9 |
149 | 19 | 31 | 1693 2003 CANCER RESEARCH 63(12):3189-3194 Ng SSW; Gutschow M; Weiss M; Hauschildt S; Teubert U; Hecker TK; Luzzio FA; Kruger EA; Eger K; Figg WD Antiangiogenic activity of N-substituted and tetrafluorinated thalidomide analogues | 4 | 6 |
150 | 19 | 40 | 1750 2003 JOURNAL OF INFECTIOUS DISEASES 187(6):946-955 Haslett PAJ; Hanekom WA; Muller G; Kaplan G Thalidomide and a thalidomide analogue drug costimulate virus-specific CD8(+) T cells in vitro | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
151 | 19 | 46 | 1752 2003 JOURNAL OF INVESTIGATIVE DERMATOLOGY 121(5):1060-1065 Deng L; Ding WH; Granstein RD Thalidomide inhibits tumor necrosis factor-alpha production and antigen presentation by Langerhans cells | 1 | 1 |
152 | 19 | 32 | 1762 2003 JOURNAL OF RHEUMATOLOGY 30(12):2627-2631 Wei JCC; Chan TW; Lin HS; Huang F; Chou CT Thalidomide for severe refractory ankylosing spondylitis: A 6-month open-label trial | 0 | 1 |
153 | 19 | 36 | 1792 2003 LEUKEMIA & LYMPHOMA 44(9):1489-1493 Steins MB; Bieker R; Padro T; Kessler T; Kienast J; Berdel WE; Mesters RM Thalidomide for the treatment of acute myeloid leukemia | 0 | 0 |
154 | 19 | 25 | 1807 2003 ORGANIC LETTERS 5(16):2865-2867 Capitosti SM; Hansen TP; Brown ML Facile synthesis of an azido-labeled thalidomide analogue | 0 | 2 |
155 | 19 | 91 | 1845 2004 ANTIOXIDANTS & REDOX SIGNALING 6(1):1-14 Hansen JM; Harris C A novel hypothesis for thalidomide-induced limb teratogenesis: Redox misregulation of the NF-kappa B pathway | 0 | 0 |
156 | 19 | 37 | 1909 2004 HAEMATOLOGICA 89(7):826-831 Cavo M; Zamagni E; Tosi P; Cellini C; Cangini D; Tacchetti P; Testoni N; Tonelli M; De Vivo A; Palareti G; Tura S; Baccarani M First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma | 0 | 0 |
157 | 18 | 23 | 620 1997 JOURNAL OF AOAC INTERNATIONAL 80(4):767-773 Reepmeyer JC; Cox DC Liquid chromatographic determination of thalidomide in tablets, capsules, and raw materials | 0 | 4 |
158 | 18 | 27 | 992 2000 INTERNATIONAL JOURNAL OF DERMATOLOGY 39(5):383-388 Walchner M; Meurer M; Plewig G; Messer G Clinical and immunologic parameters during thalidomide treatment of lupus erythematosus | 16 | 27 |
159 | 18 | 37 | 1061 2000 TOXICOLOGY AND APPLIED PHARMACOLOGY 165(3):237-244 Karrow NA; McCay JA; Brown RD; Musgrove DL; Pettit DA; Munson AE; Germolec DR; White KL Thalidomide stimulates splenic IgM antibody response and cytotoxic T lymphocyte activity and alters leukocyte subpopulation numbers in female B6C3F1 mice | 5 | 8 |
160 | 18 | 36 | 1212 2001 INFLAMMATION 25(2):91-96 Belo AV; Ferreira MAND; Bosco AA; Machado RDP; Andrade SP Differential effects of thalidomide on angiogenesis and tumor growth in mice | 0 | 2 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
161 | 18 | 26 | 1222 2001 JOURNAL OF CLINICAL ONCOLOGY 19(16):3593-3595 Rajkumar SV; Kyle RA Thalidomide in the treatment of plasma cell malignancies | 6 | 7 |
162 | 18 | 27 | 1301 2002 ARCHIVOS DE BRONCONEUMOLOGIA 38(10):492-494 Valero FC; Gonzalez VB Lung toxicity due to thalidomide | 1 | 1 |
163 | 18 | 36 | 1317 2002 BLOOD 99(3):834-839 Steins MB; Padro T; Bieker R; Ruiz S; Kropff M; Kienast J; Kessler T; Buechner T; Berdel WE; Mesters RM Efficacy and safety of thalidomide in patients with acute myeloid leukemia | 11 | 25 |
164 | 18 | 23 | 1459 2002 HAEMATOLOGICA 87(3):233-234 Tosi P; Cavo M Thalidomide in multiple myeloma: state of art | 3 | 4 |
165 | 18 | 28 | 1537 2002 ONCOLOGY-NEW YORK 16(1):22-24 Richardson P; Anderson K Using thalidomide in a patient with epithelioid leiomyosarcoma and Osler-Weber-Rendu disease - Drs. Paul Richardson and Kenneth Anderson respond | 0 | 0 |
166 | 18 | 42 | 1604 2003 BLOOD 102(1):69-77 Mileshkin L; Biagi JJ; Mitchell P; Underhill C; Grigg A; Bell R; McKendrick J; Briggs P; Seymour JF; Lillie K; Smith JG; Zeldis JB; Prince HM Multicenter phase 2 trial of thalidomide in relapsed/refractory multiple myeloma: adverse prognostic impact of advanced age | 7 | 10 |
167 | 18 | 31 | 1838 2004 ANNALS OF HEMATOLOGY 83(7):467-470 Witzens M; Moehler T; Neben K; Fruehauf S; Hartschuh W; Ho AD; Goldschmidt H Development of leukocytoclastic vasculitis in a patient with multiple myeloma during treatment with thalidomide | 0 | 0 |
168 | 17 | 41 | 348 1993 ARCHIVES OF DERMATOLOGY 129(10):1261-1264 THOMAS L; DUCROS B; SECCHI T; BALME B; MOULIN G SUCCESSFUL TREATMENT OF ADULTS LANGERHANS CELL HISTIOCYTOSIS WITH THALIDOMIDE - REPORT OF 2 CASES AND LITERATURE-REVIEW | 23 | 40 |
169 | 17 | 33 | 359 1993 CLINICAL AND EXPERIMENTAL RHEUMATOLOGY 11(5):487-493 ATRA E; SATO EI TREATMENT OF THE CUTANEOUS LESIONS OF SYSTEMIC LUPUS-ERYTHEMATOSUS WITH THALIDOMIDE | 47 | 65 |
170 | 17 | 32 | 887 2000 ANTIMICROBIAL AGENTS AND CHEMOTHERAPY 44(9):2286-2290 Verbon A; Juffermans NP; Speelman P; van Deventer SJH; ten Berge IJM; Guchelaar HJ; van der Poll T A single oral dose of thalidomide enhances the capacity of lymphocytes to secrete gamma interferon in healthy humans | 17 | 18 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
171 | 17 | 19 | 998 2000 JOINT BONE SPINE 67(4):259-261 Wendling D; Toussirot E; Michel F Thalidomide: a comeback? | 1 | 4 |
172 | 17 | 27 | 1015 2000 JOURNAL OF RHEUMATOLOGY 27(6):1429-1433 Ordi-Ros J; Cortes F; Cucurull E; Mauri M; Bujan S; Vilardell M Thalidomide in the treatment of cutaneous lupus refractory to conventional therapy | 15 | 28 |
173 | 17 | 33 | 1202 2001 HAEMATOLOGICA 86(4):409-413 Tosi P; Ronconi S; Zamagni E; Cellini C; Grafone T; Cangini D; Pileri SA; Baccarani M; Tura S; Cavo M Salvage therapy with thalidomide in multiple myeloma patients relapsing after autologous peripheral blood stem cell transplantation | 13 | 21 |
174 | 17 | 42 | 1308 2002 BIOMEDICINE & PHARMACOTHERAPY 56(1):13-19 Sampaio EP; Hernandez MO; Carvalho DS; Sarno EN Management of erythema nodosum leprosum by thalidomide: thalidomide analogues inhibit M-leprae-induced TNF alpha production in vitro | 5 | 6 |
175 | 17 | 48 | 1310 2002 BIOMEDICINE & PHARMACOTHERAPY 56(1):31-35 Shek LPC; Lim DLC Thalidomide in Behcet's disease | 7 | 11 |
176 | 17 | 24 | 1428 2002 CLINICAL CANCER RESEARCH 8(11):3377-3382 Neben K; Moehler T; Benner A; Kraemer A; Egerer G; Ho AD; Goldschmidt H Dose-dependent effect of thalidomide on overall survival in relapsed multiple myeloma | 9 | 13 |
177 | 17 | 24 | 1499 2002 JOURNAL OF INVESTIGATIVE DERMATOLOGY 119(5):1020-1026 Bastuji-Garin S; Ochonisky S; Bouche P; Gherardi RK; Duguet C; Djerradine Z; Poli F; Revuz J; Thalidomide Neuropathy Study Grp Incidence and risk factors for thalidomide neuropathy: a prospective study of 135 dermatologic patients | 9 | 12 |
178 | 17 | 38 | 1526 2002 LUPUS 11(2):67-70 Piette JC; Sbai A; Frances C Warning: thalidomide-related thrombotic risk potentially concerns patients with lupus | 3 | 5 |
179 | 17 | 35 | 1553 2002 TERATOLOGY 66(3):115-121 Stromland K; Philipson E; Gronlund MA Offspring of male and female parents with thalidomide embryopathy: Birth defects and functional anomalies | 3 | 5 |
180 | 17 | 47 | 1850 2004 BIOCHEMICAL PHARMACOLOGY 68(7):1321-1329 Fernandez-Martinez E; Morales-Rios MS; Perez-Alvarez V; Muriel P Immunomodulatory effects of thalidomide analogs on LPS-induced plasma and hepatic cytokines in the rat | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
181 | 17 | 25 | 1915 2004 INTERNATIONAL JOURNAL OF HEMATOLOGY 79(3):283-288 Hattori Y; Kakimoto T; Okamoto S; Sato N; Ikeda Y Thalidomide-induced severe neutropenia during treatment of multiple myeloma | 0 | 0 |
182 | 17 | 32 | 1924 2004 JOURNAL OF CLINICAL ONCOLOGY 22(16):3269-3276 Schey SA; Fields P; Bartlett JB; Clarke IA; Ashan G; Knight RD; Streetly M; Dalgleish AG Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma | 1 | 1 |
183 | 16 | 45 | 426 1994 SCANDINAVIAN JOURNAL OF IMMUNOLOGY 40(5):535-542 ARALACHAVES M; VILANOVA M; RIBEIRO A; PINTO J IMMUNOSTIMULATORY EFFECT OF THALIDOMIDE IN NORMAL C57BL/6 MICE IS COMPATIBLE WITH STIMULATION OF A HIGHLY CONNECTED CENTRAL IMMUNE-SYSTEM .1. | 4 | 6 |
184 | 16 | 23 | 583 1997 BRITISH JOURNAL OF RHEUMATOLOGY 36(3):353-359 Stevens RJ; Andujar C; Edwards CJ; Ames PRJ; Barwick AR; Khamashta MA; Hughes GRV Thalidomide in the treatment of the cutaneous manifestations of lupus erythematosus: Experience in sixteen consecutive patients | 36 | 49 |
185 | 16 | 27 | 715 1998 JOURNAL OF PHARMACY AND PHARMACOLOGY 50(12):1409-1416 Eriksson T; Bjorkman S; Roth B; Bjork H; Hoglund P Hydroxylated metabolites of Thalidomide: Formation in-vitro and in-vivo in man | 24 | 25 |
186 | 16 | 40 | 808 1999 GASTROENTEROLOGY 117(6):1278-1287 Vasiliauskas EA; Kam LY; Abreu-Martin MT; Hassard PV; Papadakis KA; Yang HY; Zeldis JB; Targan SR An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease | 43 | 129 |
187 | 16 | 28 | 834 1999 JOURNAL OF PHARMACEUTICAL SCIENCES 88(1):121-125 Figg WD; Raje S; Bauer KS; Tompkins A; Venzon D; Bergan R; Chen A; Hamilton M; Pluda J; Reed E Pharmacokinetics of thalidomide in an elderly prostate cancer population | 34 | 48 |
188 | 16 | 39 | 855 1999 ORGANIC LETTERS 1(10):1571-1573 Takeuchi Y; Shiragami T; Kimura K; Suzuki E; Shibata N (R)- and (S)-3-fluorothalidomides: Isosteric analogues of thalidomide | 3 | 14 |
189 | 16 | 22 | 991 2000 INTERNATIONAL JOURNAL OF DERMATOLOGY 39(3):218-222 Kyriakis KP; Kontochristopoulos GJ; Panteleos DN Experience with low-dose thalidomide therapy in chronic discoid lupus erythematosus | 10 | 17 |
190 | 16 | 59 | 1047 2000 QJM-MONTHLY JOURNAL OF THE ASSOCIATION OF PHYSICIANS 93(5):305-311 Davey PP; Ashrafian H New therapies for heart failure: is thalidomide the answer? | 6 | 9 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
191 | 16 | 37 | 1147 2001 BRITISH JOURNAL OF CANCER 85(7):953-958 Stebbing J; Benson C; Eisen T; Pyle L; Smalley K; Bridle H; Mak I; Sapunar F; Ahern R; Gore ME The treatment of advanced renal cell cancer with high-dose oral thalidomide | 19 | 31 |
192 | 16 | 47 | 1185 2001 DRUGS OF THE FUTURE 26(1):100-103 [Anon] Thalidomide - Synovir (R) - Thalomid (R) - Talizer (R) - Oncolytic treatment of IBD antiarthritic treatment of leprosy | 0 | 0 |
193 | 16 | 29 | 1413 2002 CANCER BIOLOGY & THERAPY 1(6):669-673 Ando L; Price DK; Dahut WL; Cox MC; Reed E; Figg WD Pharmacogenetic associations of CYP2C19 genotype with in vivo metabolisms and pharmacological effects of thalidomide | 0 | 0 |
194 | 16 | 34 | 1478 2002 JOURNAL OF CARDIAC FAILURE 8(5):306-314 Agoston I; Dibbs ZI; Wang F; Muller G; Zeldis JB; Mann DL; Bozkurt B Preclinical and clinical assessment of the safety and potential efficacy of thalidomide in heart failure | 2 | 3 |
195 | 16 | 24 | 1480 2002 JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES 767(1):145-151 Teo SK; Chandula RS; Harden JL; Stirling DI; Thomas SD Sensitive and rapid method for the determination of thalidomide in human plasma and semen using solid-phase extraction and liquid chromatography-tandem mass spectrometry | 4 | 5 |
196 | 16 | 25 | 1702 2003 CLINICAL LYMPHOMA 3(4):241-246 Seldin DC; Choufani EB; Dember LM; Wiesman JF; Berk JL; Falk RH; O'Hara C; Fennessey S; Finn KT; Wright DG; Skinner M; Sanchorawala V Tolerability and efficacy of thalidomide for the treatment of patients with light chain-associated (AL) amyloidosis | 5 | 9 |
197 | 16 | 37 | 1713 2003 DRUG METABOLISM AND DISPOSITION 31(4):469-475 Miyata M; Tamura E; Motoki K; Nagata K; Yamazoe Y Thalidomide-induced suppression of embryo fibroblast proliferation requires CYP1A1-mediated activation | 2 | 2 |
198 | 16 | 42 | 1730 2003 INTERNATIONAL IMMUNOPHARMACOLOGY 3(10-11):1447-1456 Karrow NA; Guo TL; Zhang LX; McCay JA; Musgrove DL; Peachee VL; Germolec DR; White KL Thalidomide modulation of the immune response in female B6C3F1 mice: a host resistance study | 0 | 1 |
199 | 16 | 33 | 1837 2004 AMERICAN JOURNAL OF VETERINARY RESEARCH 65(5):659-664 Farese JR; Fox LE; Detrisac CJ; Van Gilder JA; Roberts SL; Baldwin JA Effect of thalidomide on growth and metastasis of canine osteosarcoma cells after xenotransplantation in athymic mice | 0 | 0 |
200 | 16 | 28 | 1896 2004 EUROPEAN JOURNAL OF HAEMATOLOGY 72(1):52-57 Strupp C; Germing U; Scherer A; Kundgen A; Modder U; Gattermann N; Haas R Thalidomide for the treatment of idiopathic myelofibrosis | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
201 | 15 | 26 | 268 1990 ARCHIVES OF DERMATOLOGY 126(7):923-927 REVUZ J; GUILLAUME JC; JANIER M; HANS P; MARCHAND C; SOUTEYRAND P; BONNETBLANC JM; CLAUDY A; DALLAC S; KLENE C; CRICKX B; SANCHOGARNIER H; CHAUMEIL JC CROSSOVER STUDY OF THALIDOMIDE VS PLACEBO IN SEVERE RECURRENT APHTHOUS STOMATITIS | 53 | 100 |
202 | 15 | 43 | 422 1994 POSTGRADUATE MEDICAL JOURNAL 70(830):860-862 GARDNERMEDWIN JM; POWELL RJ THALIDOMIDE - THE WAY FORWARD | 7 | 10 |
203 | 15 | 27 | 608 1997 INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY 19(5):289-296 Pham-Huy C; Galons H; Voisin J; Zhu JR; Righenzi S; Warnet JM; Claude JR; Duc HT In vitro and in vivo immunosuppressive potential of thalidomide and its derivative, N-hydroxythalidomide, alone and in combination with cyclosporin A | 1 | 1 |
204 | 15 | 33 | 741 1998 SCANDINAVIAN JOURNAL OF IMMUNOLOGY 48(4):397-402 Zhu J; Deng GM; Diab A; Zwingenberger K; Bakhiet M; Link H Thalidomide prolongs experimental autoimmune neuritis in Lewis rats | 4 | 10 |
205 | 15 | 32 | 812 1999 IMMUNOLOGY LETTERS 68(2-3):325-332 Rowland TL; McHugh SM; Deighton J; Ewan PW; Dearman RJ; Kimber I Selective down-regulation of T cell-and non-T cell-derived tumour necrosis factor alpha by thalidomide: comparisons with dexamethasone | 10 | 13 |
206 | 15 | 32 | 972 2000 ELECTROPHORESIS 21(15):3270-3279 Meyring M; Muhlenbrock C; Blaschke G Investigation of the stereoselective in vitro biotransformation of thalidomide using a dual cyclodextrin system in capillary electrophoresis | 7 | 17 |
207 | 15 | 25 | 999 2000 JOURNAL OF BIOCHEMICAL AND MOLECULAR TOXICOLOGY 14(3):140-147 Teo SK; Sabourin PJ; O'Brien K; Kook KA; Thomas SD Metabolism of thalidomide in human microsomes, cloned human cytochrome P-450 isozymes, and Hansen's disease patients | 22 | 22 |
208 | 15 | 19 | 1018 2000 LEPROSY REVIEW 71:S117-S120 Kaplan G Potential of thalidomide and thalidomide analogues as immunomodulatory drugs in leprosy and leprosy reactions | 1 | 2 |
209 | 15 | 17 | 1275 2001 SEMINARS IN ONCOLOGY 28(6):602-606 Stirling D Thalidomide: A novel template for anticancer drugs | 8 | 13 |
210 | 15 | 82 | 1309 2002 BIOMEDICINE & PHARMACOTHERAPY 56(1):20-30 Zorat F; Pozzato G Thalidomide in myelodysplastic syndromes | 3 | 3 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
211 | 15 | 35 | 1463 2002 HAEMATOLOGICA 87(4):408-414 Tosi P; Zamagni E; Cellini C; Ronconi S; Patriarca F; Ballerini F; Musto P; Di Raimondo F; Ledda A; Lauria F; Masini L; Gobbi M; Vacca A; Ria R; Cangini D; Tura S; Baccarani M; Cavo M Salvage therapy with thalidomide in patients with advanced relapsed/refractory multiple myeloma | 19 | 29 |
212 | 15 | 47 | 1602 2003 BLOOD 101(7):2534-2541 Mesa RA; Steensma DP; Pardanani A; Li CY; Elliott M; Kaufmann SH; Wiseman G; Gray LA; Schroeder GE; Reeder T; Zeldis JB; Tefferi A A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia | 6 | 10 |
213 | 15 | 45 | 1755 2003 JOURNAL OF MEDICINAL CHEMISTRY 46(24):5222-5229 Zhu XX; Giordano T; Yu QS; Holloway HW; Perry TA; Lahiri DK; Brossi A; Greig NH Thiothalidomides: Novel isosteric analogues of thalidomide with enhanced TNF-alpha inhibitory activity | 2 | 2 |
214 | 15 | 21 | 1811 2003 PHARMACOTHERAPY 23(3):315-318 Horne MK; Figg WD; Arlen P; Gulley J; Parker C; Lakhani N; Parnes H; Dahut WL Increased frequency of venous thromboembolism with the combination of docetaxel and thalidomide in patients with metastatic androgen-independent prostate cancer | 3 | 4 |
215 | 15 | 16 | 1834 2004 AMERICAN JOURNAL OF CARDIOLOGY 93(8):1052-1055 Fahdi IE; Gaddam V; Saucedo JF; Kishan CV; Vyas K; Deneke MG; Razek H; Thorn B; Bissett JK; Anaisse E; Barlogie B; Mehta JL Bradycardia during therapy for multiple myeloma with thalidomide | 0 | 0 |
216 | 15 | 15 | 1875 2004 CANADIAN JOURNAL OF GASTROENTEROLOGY 18(2):101-104 Hershfield NB Disappearance of Chron's ulcers in the terminal ileum after thalidomide therapy | 0 | 0 |
217 | 15 | 30 | 1897 2004 EUROPEAN JOURNAL OF HAEMATOLOGY 72(6):403-409 Offidani M; Corvatta L; Marconi M; Malerba L; Mele A; Olivieri A; Brunori M; Catarini M; Candela M; Capelli D; Montanari M; Rupoli S; Leoni P Common and rare side-effects of low-dose thalidomide in multiple myeloma: focus on the dose-minimizing peripheral neuropathy | 0 | 0 |
218 | 15 | 59 | 1951 2004 LEUKEMIA RESEARCH 28(4):325-332 Musto P Thalidomide therapy for myelodysplastic syndromes: current status and future perspectives | 0 | 0 |
219 | 15 | 44 | 1954 2004 MAYO CLINIC PROCEEDINGS 79(7):857-858 Silver RT Myelofibrosis: Thalidomide finds a new disease | 0 | 0 |
220 | 15 | 16 | 1966 2004 NEUROLOGY 62(12):2158-2159 Apfel SC; Zochodne DW Thalidomide neuropathy - Too much or too long? | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
221 | 14 | 22 | 402 1994 DERMATOLOGY 189(2):179-181 BIELSA I; TEIXIDO J; RIBERA M; FERRANDIZ C ERYTHRODERMA DUE TO THALIDOMIDE - REPORT OF 2 CASES | 13 | 17 |
222 | 14 | 25 | 445 1995 CHIRALITY 7(1):44-52 ERIKSSON T; BJORKMAN S; ROTH B; FYGE A; HOGLUND P STEREOSPECIFIC DETERMINATION, CHIRAL INVERSION IN-VITRO AND PHARMACOKINETICS IN HUMANS OF THE ENANTIOMERS OF THALIDOMIDE | 57 | 80 |
223 | 14 | 44 | 469 1995 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 32(5):866-869 CARLESIMO M; GIUSTINI S; ROSSI A; BONACCORSI P; CALVIERI S TREATMENT OF CUTANEOUS AND PULMONARY SARCOIDOSIS WITH THALIDOMIDE | 48 | 84 |
224 | 14 | 38 | 474 1995 LIFE SCIENCES 58(4):295-316 Neubert R; Hinz N; Thiel R; Neubert D Down-regulation of adhesion receptors on cells of primate embryos as a probable mechanism of the teratogenic action of thalidomide | 3 | 7 |
225 | 14 | 24 | 524 1996 EUROPEAN JOURNAL OF DERMATOLOGY 6(5):373-376 Charue D; Chauvin E; Duguet C; Revuz J; Bagot M Thalidomide decreases the production of GM-CSF and TNF-alpha in the mixed epidermal cell-lymphocyte reaction | 1 | 2 |
226 | 14 | 26 | 543 1996 JOURNAL OF MEDICINAL CHEMISTRY 39(17):3238-3240 Muller GW; Corral LG; Shire MG; Wang H; Moreira A; Kaplan G; Stirling DI Structural modifications of thalidomide produce analogs with enhanced tumor necrosis factor inhibitory activity | 34 | 49 |
227 | 14 | 23 | 681 1998 BONE MARROW TRANSPLANTATION 21(6):577-581 Rovelli A; Arrigo C; Nesi F; Balduzzi A; Nicolini B; Locasiulli A; Vassallo E; Miniero R; Uderzo C The role of thalidomide in the treatment of refractory chronic graft-versus-host disease following bone marrow transplantation in children | 27 | 37 |
228 | 14 | 30 | 709 1998 JOURNAL OF IMMUNOLOGY 161(8):4236-4243 Marriott JB; Westby M; Cookson S; Guckian M; Goodbourn S; Muller G; Shire MG; Stirling D; Dalgleish AG CC-3052: A water-soluble analog of thalidomide and potent inhibitor of activation-induced TNF-alpha production | 34 | 50 |
229 | 14 | 32 | 1090 2001 BIOORGANIC & MEDICINAL CHEMISTRY 9(4):1059-1065 Gutschow M; Hecker T; Thiele A; Hauschildt S; Eger K Aza analogues of thalidomide: Synthesis and evaluation as inhibitors of tumor necrosis factor-alpha production in vitro | 3 | 8 |
230 | 14 | 63 | 1181 2001 DRUG DEVELOPMENT RESEARCH 54(4):209-218 Fernandez-Martinez E; Morales-Rios MS; Perez-Alvarez V; Muriel P Effects of thalidomide and 3-phthalimido-3-(3,4-dimethoxyphenyl)-propanamide on bile duct obstruction-induced cirrhosis in the rat | 2 | 3 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
231 | 14 | 29 | 1420 2002 CHEST 122(1):227-232 Baughman RP; Judson MA; Teirstein AS; Moller DR; Lower EE Thalidomide for chronic sarcoidosis | 4 | 27 |
232 | 14 | 18 | 1424 2002 CLINICAL AND EXPERIMENTAL RHEUMATOLOGY 20(6):S158-S161 Huang F; Wei JCC; Breban M Thalidomide in ankylosing spondylitis | 0 | 1 |
233 | 14 | 22 | 1462 2002 HAEMATOLOGICA 87(4):345-346 [Anon] Inside Haematologica: caution in the use of thalidomide for treatment of hematologic disorders | 0 | 0 |
234 | 14 | 28 | 1476 2002 JAPANESE JOURNAL OF CANCER RESEARCH 93(9):1029-1036 Kakimoto T; Hattori Y; Okamoto S; Sato N; Kamata T; Yamaguchi M; Morita K; Yamada T; Takayama N; Uchida H; Shimada N; Tanigawara Y; Ikeda Y Thalidomide for the treatment of refractory multiple myeloma: Association of plasma concentrations of thalidomide and angiogenic growth factors with clinical outcome | 3 | 3 |
235 | 14 | 24 | 1585 2003 ANTIMICROBIAL AGENTS AND CHEMOTHERAPY 47(8):2445-2449 Giamarellos-Bourboulis EJ; Poulaki H; Kostomitsopoulos N; Dontas I; Perrea D; Karayannacos PE; Giamarellou H Effective immunomodulatory treatment of Escherichia coli experimental sepsis with thalidomide | 0 | 1 |
236 | 14 | 32 | 1736 2003 INVESTIGATIONAL NEW DRUGS 21(3):359-366 Dal Lago L; Richter MF; Cancela AI; Fernandes SA; Jung KT; Rodrigues AC; Dalla Costa T; Di Leone LP; Schwartsmann G Phase II trial and pharmacokinetic study of thalidomide in patients with metastatic colorectal cancer | 1 | 1 |
237 | 14 | 23 | 1820 2003 SEMINARS IN HEMATOLOGY 40(4):8-16 Dimopoulos MA; Anagnostopoulos A Thalidomide in relapsed/refractory multiple myeloma: Pivotal trials conducted outside the United States | 0 | 0 |
238 | 14 | 23 | 1917 2004 INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS 60(2):353-357 Chang SM; Lamborn KR; Malec M; Larson D; Wara W; Sneed P; Rabbitt J; Page M; Nicholas MK; Prados MD Phase II study of temozolomide and thalidomide with radiation therapy for newly diagnosed glioblastoma multiforme | 0 | 0 |
239 | 14 | 23 | 1930 2004 JOURNAL OF MEDICINAL CHEMISTRY 47(9):2219-2227 Lepper ER; Ng SSW; Gutschow M; Weiss M; Hauschildt S; Hecker TK; Luzzio FA; Eger K; Figg WD Comparative molecular field analysis and comparative molecular similarity indices analysis of thalidomide analogues as angiogenesis inhibitors | 0 | 0 |
240 | 14 | 27 | 1934 2004 JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS 310(2):571-577 Lu J; Helsby N; Palmer BD; Tingle M; Baguley BC; Kestell P; Ching LM Metabolism of thalidomide in liver microsomes of mice, rabbits, and humans | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
241 | 14 | 20 | 1949 2004 LEUKEMIA & LYMPHOMA 45(4):735-738 Balleari E; Ghio R; Falcone A; Musto P Possible multiple myeloma dedifferentiation following thalidomide therapy: A report of four cases | 0 | 0 |
242 | 14 | 27 | 1969 2004 ONCOLOGY REPORTS 11(1):93-95 Morabito A; Fanelli M; Carillio G; Gattuso D; Sarmiento R; Gasparini G Thalidomide prolongs disease stabilization after conventional therapy in patients with recurrent glioblastoma | 0 | 0 |
243 | 14 | 24 | 1970 2004 ONKOLOGIE 27(2):150-154 Steurer M; Spizzo G; Mitterer M; Gastl G Low-dose thalidomide for multiple myeloma: Interim analysis of a compassionate use program | 0 | 0 |
244 | 14 | 32 | 1975 2004 UROLOGY 63(6):1061-1065 Clark PE; Hall MC; Miller A; Ridenhour KP; Stindt D; Lovato JF; Patton SE; Brinkley W; Das S; Torti FM Phase II trial of combination interferon-alpha and thalidomide as first-line therapy in metastatic renal cell carcinoma | 0 | 0 |
245 | 13 | 39 | 262 1989 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 20(6):1060-1063 GRINSPAN D; BLANCO GF; AGUERO S TREATMENT OF APHTHAE WITH THALIDOMIDE | 9 | 24 |
246 | 13 | 34 | 447 1995 CLINICAL AND EXPERIMENTAL IMMUNOLOGY 99(2):160-167 MCHUGH SM; RIFKIN IR; DEIGHTON J; WILSON AB; LACHMANN PJ; LOCKWOOD CM; EWAN PW THE IMMUNOSUPPRESSIVE DRUG THALIDOMIDE INDUCES T-HELPER CELL-TYPE 2 (TH2) AND CONCOMITANTLY INHIBITS TH1 CYTOKINE PRODUCTION IN MITOGEN-STIMULATED AND ANTIGEN-STIMULATED HUMAN PERIPHERAL-BLOOD MONONUCLEAR CELL-CULTURES | 108 | 145 |
247 | 13 | 22 | 517 1996 CHIRALITY 8(5):390-396 Wnendt S; Finkam M; Winter W; Ossig J; Raabe G; Zwingenberger K Enantioselective inhibition of TNF-alpha release by thalidomide and thalidomide-analogues | 28 | 34 |
248 | 13 | 27 | 701 1998 GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY 236(6):461-466 Kruse FE; Joussen AM; Rohrschneider K; Becker MD; Volcker HE Thalidomide inhibits corneal angiogenesis induced by vascular endothelial growth factor | 39 | 57 |
249 | 13 | 66 | 727 1998 MEDICAL HYPOTHESES 50(4):313-318 Argiles JM; Carbo N; Lopez-Soriano FJ Was tumour necrosis factor-alpha responsible for the fetal malformations associated with thalidomide in the early 1960s? | 11 | 12 |
250 | 13 | 16 | 789 1999 CLEVELAND CLINIC JOURNAL OF MEDICINE 66(3):136-+ Calabrese LH Thalidomide's tightly controlled "comeback" | 3 | 3 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
251 | 13 | 35 | 864 1999 SKIN PHARMACOLOGY AND APPLIED SKIN PHYSIOLOGY 12(6):305-311 Monastirli A; Georgiou S; Bolsen K; Pasmatzi E; Papapanagiotou A; Goerz G; Kalofoutis A; Merk HF; Tsambaos D Treatment of porphyria cutanea tarda with oral thalidomide | 5 | 7 |
252 | 13 | 40 | 867 1999 SURGERY 125(5):536-544 Kotoh T; Dhar DK; Masunaga R; Tabara H; Tachibana M; Kubota H; Kohno H; Nagasue N Antiangiogenic therapy of human esophageal cancers with thalidomide in nude mice | 12 | 27 |
253 | 13 | 32 | 873 2000 AIDS RESEARCH AND HUMAN RETROVIRUSES 16(14):1345-1355 Kaplan G; Thomas S; Fierer DS; Mulligan K; Haslett PAJ; Fessel WJ; Smith LG; Kook KA; Stirling D; Schambelan M Thalidomide for the treatment of AIDS-associated wasting | 13 | 28 |
254 | 13 | 33 | 895 2000 BIOPHARMACEUTICS & DRUG DISPOSITION 21(1):33-40 Teo SK; Scheffler MR; Kook KA; Tracewell WG; Colburn WA; Stirling DI; Thomas SD Effect of a high-fat meal on thalidomide pharmacokinetics and the relative bioavailability of oral formulations in healthy men and women | 6 | 6 |
255 | 13 | 49 | 958 2000 CLINICAL AND EXPERIMENTAL IMMUNOLOGY 121(3):472-479 Guckian M; Dransfield I; Hay P; Dalgleish AG Thalidomide analogue CC-3052 reduces HIV+ neutrophil apoptosis in vitro | 4 | 6 |
256 | 13 | 49 | 960 2000 CLINICAL IMMUNOLOGY 97(2):109-120 Oliver SJ; Moreira A; Kaplan G Immune stimulation in scleroderma patients treated with thalidomide | 11 | 15 |
257 | 13 | 41 | 1002 2000 JOURNAL OF CHROMATOGRAPHY A 876(1-2):157-167 Meyring M; Chankvetadze B; Blaschke G Simultaneous separation and enantioseparation of thalidomide and its hydroxylated metabolites using high-performance liquid chromatography in common-size columns, capillary liquid chromatography and nonaqueous capillary electrochromatography | 3 | 32 |
258 | 13 | 67 | 1004 2000 JOURNAL OF CLINICAL ONCOLOGY 18(13):2593-2602 Little RF; Wyvill KM; Pluda JM; Welles L; Marshall V; Figg WD; Newcomb FM; Tosato G; Feigal E; Steinberg SM; Whitby D; Goedert JJ; Yarchoan R Activity of thalidomide in AIDS-related Kaposis's sarcoma | 45 | 83 |
259 | 13 | 22 | 1056 2000 TERATOGENESIS CARCINOGENESIS AND MUTAGENESIS 20(5):301-311 Teo S; Morgan M; Stirling D; Thomas S Assessment of the in vitro and in vivo genotoxicity of Thalomid (R) (Thalidomide) | 1 | 1 |
260 | 13 | 41 | 1091 2001 BIOORGANIC & MEDICINAL CHEMISTRY 9(5):1279-1291 Hess S; Akermann MA; Wnendt S; Zwingerberger K; Eger K Synthesis and immunological activity of water-soluble thalidomide prodrugs | 2 | 4 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
261 | 13 | 23 | 1213 2001 INTERNATIONAL IMMUNOPHARMACOLOGY 1(1):49-61 Rowland TL; McHugh SM; Deighton J; Ewan PW; Dearman RJ; Kimber I Differential effect of thalidomide and dexamethasone on the transcription factor NF-kappa B | 5 | 8 |
262 | 13 | 29 | 1244 2001 MUSCLE & NERVE 24(8):1050-1057 Molloy FM; Floeter MK; Syed NA; Sandbrink F; Culcea E; Steinberg SM; Dahut W; Pluda J; Kruger EA; Reed E; Figg WD Thalidomide neuropathy in patients treated for metastatic prostate cancer | 12 | 17 |
263 | 13 | 18 | 1265 2001 REVUE DE MEDECINE INTERNE 22(1):5-7 Grosbois B; Duguet C Thalidomide: the revival | 2 | 4 |
264 | 13 | 27 | 1286 2002 AMERICAN HEART JOURNAL 144(5):847-850 Gullestad L; Semb AG; Holt E; Skardal R; Ueland T; Yndestad A; Froland SS; Aukrust P Effect of thalidomide in patients with chronic heart failure | 1 | 4 |
265 | 13 | 40 | 1291 2002 ANALYTICAL CHEMISTRY 74(15):3726-3735 Meyring M; Muhlbacher J; Messer K; Kastner-Pustet N; Bringmann G; Mannschreck A; Blaschke G In vitro biotransformation of (R)- and (S)-thalidomide: Application of circular dichroism spectroscopy to the stereochemical characterization of the hydroxylated metabolites | 0 | 3 |
266 | 13 | 33 | 1411 2002 CANCER 95(4):758-765 Daliani DD; Papandreou CN; Thall PF; Wang XM; Perez C; Oliva R; Pagliaro L; Amato R A pilot study of thalidomide in patients with progressive metastatic renal cell carcinoma | 6 | 11 |
267 | 13 | 14 | 1443 2002 EUROPEAN JOURNAL OF DERMATOLOGY 12(1):63-65 Frances C; El Khoury S; Gompel A; Becherel PA; Chosidow O; Piette JC Transient secondary amenorrhea in women treated by thalidomide | 1 | 2 |
268 | 13 | 36 | 1458 2002 GUT 50(2):196-200 Bauditz J; Wedel S; Lochs H Thalidomide reduces tumour necrosis factor alpha and interleukin 12 production in patients with chronic active Crohn's disease | 11 | 25 |
269 | 13 | 20 | 1461 2002 HAEMATOLOGICA 87(4):344-345 Ribatti D; Vacca A Is thalidomide a true anti-angiogenic molecule in multiple myeloma? | 1 | 1 |
270 | 13 | 15 | 1467 2002 HAUTARZT 53(11):744-748 Bohmeyer J; Achenbach A; Westenberger M; Stadler R Thalidomide therapy of cutaneous lupus erythematosus | 1 | 1 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
271 | 13 | 25 | 1492 2002 JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY 17(2):135-139 Bariol C; Meagher AP; Vickers CR; Byrnes DJ; Edwards PD; Hing M; Wettstein AR; Field A Early studies on the safety and efficacy of thalidomide for symptomatic inflammatory bowel disease | 8 | 13 |
272 | 13 | 15 | 1496 2002 JOURNAL OF INFECTIOUS DISEASES 185(9):1359-1363 Wohl DA; Aweeka FT; Schmitz J; Pomerantz R; Cherng DW; Spritzler J; Fox L; Simpson D; Bell D; Holohan MK; Thomas S; Robinson W; Kaplan G; Teppler H; Natl Inst Allergy Infect Dis AIDS Safety, tolerability, and pharmacokinetic effects of thalidomide in patients infected with human immunodeficiency virus: AIDS Clinical Trials Group 267 | 5 | 5 |
273 | 13 | 29 | 1534 2002 NEUROLOGY 59(12):1872-1875 Chaudhry V; Cornblath DR; Corse A; Freimer M; Simmons-O'Brien E; Vogelsang G Thalidomide-induced neuropathy | 7 | 9 |
274 | 13 | 25 | 1589 2003 ARCHIVES OF DERMATOLOGY 139(2):136-138 Thomas P; Walchner M; Ghoreschi K; Rocken M Successful treatment of granulomatous cheilitis with thalidomide | 0 | 0 |
275 | 13 | 35 | 1666 2003 BONE MARROW TRANSPLANTATION 32(2):165-170 Kulkarni S; Powles R; Sirohi B; Treleaven J; Saso R; Horton C; Atra A; Ortin M; Rudin C; Goyal S; Sankpal S; Meller S; Pinkerton CR; Mehta J; Singhal S Thalidomide after allogeneic haematopoietic stem cell transplantation: activity in chronic but not in acute graft-versus-host disease | 1 | 2 |
276 | 13 | 38 | 1708 2003 CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY 46:S59-S65 Amato RJ Thalidomide therapy for renal cell carcinoma | 0 | 1 |
277 | 13 | 23 | 1735 2003 INTERNATIONAL JOURNAL OF ONCOLOGY 23(6):1651-1655 Kaicker S; McCrudden KW; Beck L; New T; Huang JZ; Frischer JS; Serur A; Kadenhe-Chiweshe A; Yokoi A; Kandel JJ; Yamashiro DJ Thalidomide is anti-angiogenic in a xenograft model of neuroblastoma | 0 | 0 |
278 | 13 | 36 | 1746 2003 JOURNAL OF CLINICAL ONCOLOGY 21(20):3770-3776 Hernberg M; Virkkunen P; Bono P; Atinen H; Maenpaa H; Joensuu H Interferon alfa-2b three times daily and thalidomide in the treatment of metastatic renal cell carcinoma | 2 | 4 |
279 | 13 | 23 | 1761 2003 JOURNAL OF PHARMACY AND PHARMACOLOGY 55(12):1701-1706 Eriksson T; Hoglund P; Turesson I; Waage A; Don BR; Vu J; Scheffler M; Kaysen GA Pharmacokinetics of thalidomide in patients with impaired renal function and while on and off dialysis | 3 | 3 |
280 | 13 | 57 | 1787 2003 LEUKEMIA & LYMPHOMA 44(2):291-298 Ribas C; Colleoni GWB Advances in the treatment of multiple myeloma: The role of thalidomide | 0 | 1 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
281 | 13 | 44 | 1805 2003 ONCOLOGY 65(3):242-249 Hsu C; Chen CN; Chen LT; Wu CY; Yang PM; Lai MY; Lee PH; Cheng AL Low-dose thalidomide treatment for advanced hepatocellular carcinoma | 2 | 5 |
282 | 13 | 28 | 1879 2004 CANCER CHEMOTHERAPY AND PHARMACOLOGY 53(5):377-383 Chung F; Wang LCS; Kestell P; Baguley BC; Ching LM Modulation of thalidomide pharmacokinetics by cyclophosphamide or 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice: the role of tumour necrosis factor | 2 | 2 |
283 | 13 | 26 | 1919 2004 JOURNAL OF CHILD NEUROLOGY 19(4):250-257 Schoeman JF; Springer P; van Rensburg AJ; Swanevelder S; Hanekom WA; Haslett PAJ; Kaplan G Adjunctive thalidomide therapy for childhood tuberculous meningitis: Results of a randomized study | 0 | 0 |
284 | 13 | 23 | 1937 2004 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 51(1):126-131 Sansbury JC; Cocuroccia B; Jorizzo JL; Gubinelli E; Gisondi P; Girolomoni G Treatment of recalcitrant scleromyxedema with thalidomide in 3 patients | 0 | 0 |
285 | 13 | 19 | 1972 2004 THROMBOSIS AND HAEMOSTASIS 91(4):834-836 Potenza L; Luppi M; Morselli M; Saviola A; Ferrari A; Riva G; Longo G; Marietta M; Torelli G Thrombotic complications associated with thalidomide in multiple myeloma: an old problem with new questions and quandaries in decision-making | 0 | 0 |
286 | 12 | 23 | 382 1994 ARCHIVES OF DERMATOLOGY 130(1):66-69 OCHONISKY S; VERROUST J; BASTUJIGARIN S; GHERARDI R; REVUZ J THALIDOMIDE NEUROPATHY INCIDENCE AND CLINICOELECTROPHYSIOLOGIC FINDINGS IN 42 PATIENTS | 73 | 97 |
287 | 12 | 43 | 567 1997 AIDS RESEARCH AND HUMAN RETROVIRUSES 13(10):857-863 Moreira AL; Corral LG; Ye WG; Johnson B; Stirling D; Muller GW; Freedman VH; Kaplan G Thalidomide and thalidomide analogs reduce HIV type 1 replication in human macrophages in vitro | 36 | 47 |
288 | 12 | 21 | 576 1997 ANTIMICROBIAL AGENTS AND CHEMOTHERAPY 41(12):2797-2799 Piscitelli SC; Figg WD; Hahn B; Kelly G; Thomas S; Walker RE Single-dose pharmacokinetics of thalidomide in human immunodeficiency virus-infected patients | 22 | 25 |
289 | 12 | 27 | 578 1997 BIOCHEMICAL PHARMACOLOGY 53(10):1553-1557 Nicolai S; Sies H; Stahl W Stimulation of gap junctional intercellular communication by thalidomide and thalidomide analogs in human skin fibroblasts | 6 | 11 |
290 | 12 | 21 | 586 1997 CHEMTECH 27(1):21-25 Muller GW Thalidomide: From tragedy to new drug discovery | 4 | 9 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
291 | 12 | 33 | 714 1998 JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS 26(4):363-383 Hoglund P; Eriksson T; Bjorkman S A double-blind study of the sedative effects of the thalidomide enantiomers in humans | 11 | 15 |
292 | 12 | 39 | 746 1999 AIDS RESEARCH AND HUMAN RETROVIRUSES 15(13):1169-1179 Haslett PAJ; Klausner JD; Makonkawkeyoon S; Moreira A; Metatratip P; Boyle B; Kunachiwa W; Maneekarn N; Vongchan P; Corral LG; Elbeik T; Shen Z; Kaplan G Thalidomide stimulates T cell responses and interleukin 12 production in HIV-infected patients | 27 | 33 |
293 | 12 | 70 | 800 1999 DRUGS 58(6):953-963 Ravot E; Lisziewicz J; Lori F New uses for old drugs in HIV infection - The role of hydroxyurea, cyclosporin and thalidomide | 3 | 15 |
294 | 12 | 34 | 801 1999 ELECTROPHORESIS 20(12):2425-2431 Meyring M; Chankvetadze B; Blaschke G Enantioseparation of thalidomide and its hydroxylated metabolites using capillary electrophoresis with various cyclodextrins and their combinations as chiral buffer additives | 2 | 13 |
295 | 12 | 27 | 821 1999 JCR-JOURNAL OF CLINICAL RHEUMATOLOGY 5(5):261-267 Scoville CD; Reading JC Open trial of thalidomide in the treatment of rheumatoid arthritis | 1 | 1 |
296 | 12 | 23 | 833 1999 JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION 28(2):214-216 Weinstein TA; Sciubba JJ; Levine J Thalidomide for the treatment of oral aphthous ulcers in Crohn's disease | 10 | 21 |
297 | 12 | 17 | 863 1999 REVUE DE MEDECINE INTERNE 20(7):567-570 de Wazieres B; Gil H; Magy N; Berthier S; Vuitton DA; Dupond JL Treatment of recurrent oro-genital ulceration with low dose of thalidomide. Pilot study in 17 patients | 3 | 9 |
298 | 12 | 33 | 961 2000 CLINICAL INFECTIOUS DISEASES 30(5):826-831 Aboulafia DM Inflammatory pseudotumor causing small bowel obstruction and mimicking lymphoma in a patient with AIDS: Clinical improvement after initiation of thalidomide treatment | 1 | 4 |
299 | 12 | 20 | 988 2000 IMMUNOPHARMACOLOGY 46(2):175-179 Shannon E; Aseffa A; Pankey G; Sandoval F; Lutz B Thalidomide's ability to augment the synthesis of IL-2 in vitro in HIV-infected patients is associated with the percentage of CD4+cells in their blood | 8 | 8 |
300 | 12 | 44 | 1007 2000 JOURNAL OF INFECTIOUS DISEASES 181(3):954-965 Bekker LG; Haslett P; Maartens G; Steyn L; Kaplan G Thalidomide-induced antigen-specific immune stimulation in patients with human immunodeficiency virus type 1 and tuberculosis | 18 | 27 |